RxDoctor Payments Data

Christopher Vaccari, MD

Cardiovascular Disease · Hagerstown, MDNPI 1912092115

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,068 of the $15,008 with a category attached, or 87.1%. Amgen accounts for 90.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $13,658 and has fallen 95.4% since, to $635 in 2025.

$15,008in general payments, 2019–2025

Across 93 payments — averaging $161.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • E.r. Squibb & Sons, L.L.C.$550
  • Baxter Healthcare$243
  • Esperion Therapeutics, Inc.$103
  • Medtronic$100
  • Novo Nordisk$97
  • plus $375 from 11 others
$16,097in research payments, 2019–2025

Across 8 payments — averaging $2012.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$16K

What the payments were for

  • Speaking & faculty fees$13,06887%
  • Travel & lodging$2031%
  • Food & beverage$1,64011%
  • Education$971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,008 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$881,054
Medicare patients
2,542
Services billed
10,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$241,042
XareltoRivaroxaban31$40,987
EntrestoSacubitril/Valsartan22$29,835
Repatha SureclickEvolocumab38$27,832
NexletolBempedoic Acid11$5,042
Atorvastatin Calcium89$2,478
Metoprolol Succinate121$2,257
Ezetimibe47$1,774
Diltiazem 24hr Er (Cd)Diltiazem Hcl74$1,678
Digoxin35$916
Nebivolol Hcl12$862
Bumetanide15$772
Valsartan11$715
Rosuvastatin Calcium41$698
Amiodarone Hcl48$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$241,042197 claims
Johnson & JohnsonXarelto$29$40,98731 claims
Esperion Therapeutics, Inc.Nexletol$103$5,04211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →